Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 158,023 shares, a growth of 20,081.7% from the June 15th total of 783 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 30,391 shares, the days-to-cover ratio is presently 5.2 days.

Institutional Investors Weigh In On Ascentage Pharma Group International

Institutional investors and hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the second quarter worth $391,000. UBS Group AG grew its stake in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares in the last quarter. XY Capital Ltd grew its stake in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the third quarter worth approximately $383,000.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. B. Riley Financial began coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price for the company. Finally, Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Up 5.7%

Ascentage Pharma Group International stock traded up $1.07 during midday trading on Friday, reaching $19.97. The stock had a trading volume of 3,586 shares, compared to its average volume of 19,701. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. Ascentage Pharma Group International has a 52-week low of $16.36 and a 52-week high of $48.45. The company has a fifty day moving average of $18.99 and a 200 day moving average of $22.95.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.